Cargando…
A double‐blind, placebo‐controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss
Mirtazapine is classified as a weight gain drug in cats, and the purpose of this study was to evaluate its efficacy in cats experiencing unintended weight loss. This was a multi‐center, double‐blind, placebo‐controlled, randomized clinical study in client‐owned cats ≥1 year of age, weighing ≥2 kg, w...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379659/ https://www.ncbi.nlm.nih.gov/pubmed/30506924 http://dx.doi.org/10.1111/jvp.12738 |
_version_ | 1783562691233710080 |
---|---|
author | Poole, Melinda Quimby, Jessica M. Hu, Tianhua Labelle, Daizie Buhles, William |
author_facet | Poole, Melinda Quimby, Jessica M. Hu, Tianhua Labelle, Daizie Buhles, William |
author_sort | Poole, Melinda |
collection | PubMed |
description | Mirtazapine is classified as a weight gain drug in cats, and the purpose of this study was to evaluate its efficacy in cats experiencing unintended weight loss. This was a multi‐center, double‐blind, placebo‐controlled, randomized clinical study in client‐owned cats ≥1 year of age, weighing ≥2 kg, with a documented loss (≥5%) in body weight. Cats were treated once daily with either 2 mg/cat mirtazapine transdermal ointment (n = 83) or placebo (n = 94) (Per Protocol population) applied to the inner surface of the pinna for 14 ± 3 days. Physical examination, body weight, complete blood count, serum chemistry, and urinalysis were performed prior to treatment and on Day 14. Changes in body weight between the mirtazapine and placebo groups were evaluated from Day 1 to Day 14 and compared using a two‐sample t test. The mean percent change in body weight was +3.9% (standard deviation ±5.4%) in the mirtazapine group and +0.4% (±3.3%) in the placebo group (p < 0.0001). The most common adverse event was mild erythema at the application site in 17.4% of placebo and 10.4% of mirtazapine‐treated cats. Application of mirtazapine transdermal ointment was well tolerated both topically and systemically and resulted in significant weight gain in cats experiencing unintended weight loss associated with various underlying diseases. |
format | Online Article Text |
id | pubmed-7379659 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73796592020-07-24 A double‐blind, placebo‐controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss Poole, Melinda Quimby, Jessica M. Hu, Tianhua Labelle, Daizie Buhles, William J Vet Pharmacol Ther Scientific Papers Mirtazapine is classified as a weight gain drug in cats, and the purpose of this study was to evaluate its efficacy in cats experiencing unintended weight loss. This was a multi‐center, double‐blind, placebo‐controlled, randomized clinical study in client‐owned cats ≥1 year of age, weighing ≥2 kg, with a documented loss (≥5%) in body weight. Cats were treated once daily with either 2 mg/cat mirtazapine transdermal ointment (n = 83) or placebo (n = 94) (Per Protocol population) applied to the inner surface of the pinna for 14 ± 3 days. Physical examination, body weight, complete blood count, serum chemistry, and urinalysis were performed prior to treatment and on Day 14. Changes in body weight between the mirtazapine and placebo groups were evaluated from Day 1 to Day 14 and compared using a two‐sample t test. The mean percent change in body weight was +3.9% (standard deviation ±5.4%) in the mirtazapine group and +0.4% (±3.3%) in the placebo group (p < 0.0001). The most common adverse event was mild erythema at the application site in 17.4% of placebo and 10.4% of mirtazapine‐treated cats. Application of mirtazapine transdermal ointment was well tolerated both topically and systemically and resulted in significant weight gain in cats experiencing unintended weight loss associated with various underlying diseases. John Wiley and Sons Inc. 2018-12-02 2019-03 /pmc/articles/PMC7379659/ /pubmed/30506924 http://dx.doi.org/10.1111/jvp.12738 Text en © 2018 The Authors. Journal of Veterinary Pharmacology and Therapeutics Published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Scientific Papers Poole, Melinda Quimby, Jessica M. Hu, Tianhua Labelle, Daizie Buhles, William A double‐blind, placebo‐controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss |
title | A double‐blind, placebo‐controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss |
title_full | A double‐blind, placebo‐controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss |
title_fullStr | A double‐blind, placebo‐controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss |
title_full_unstemmed | A double‐blind, placebo‐controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss |
title_short | A double‐blind, placebo‐controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss |
title_sort | double‐blind, placebo‐controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss |
topic | Scientific Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379659/ https://www.ncbi.nlm.nih.gov/pubmed/30506924 http://dx.doi.org/10.1111/jvp.12738 |
work_keys_str_mv | AT poolemelinda adoubleblindplacebocontrolledrandomizedstudytoevaluatetheweightgaindrugmirtazapinetransdermalointmentincatswithunintendedweightloss AT quimbyjessicam adoubleblindplacebocontrolledrandomizedstudytoevaluatetheweightgaindrugmirtazapinetransdermalointmentincatswithunintendedweightloss AT hutianhua adoubleblindplacebocontrolledrandomizedstudytoevaluatetheweightgaindrugmirtazapinetransdermalointmentincatswithunintendedweightloss AT labelledaizie adoubleblindplacebocontrolledrandomizedstudytoevaluatetheweightgaindrugmirtazapinetransdermalointmentincatswithunintendedweightloss AT buhleswilliam adoubleblindplacebocontrolledrandomizedstudytoevaluatetheweightgaindrugmirtazapinetransdermalointmentincatswithunintendedweightloss AT poolemelinda doubleblindplacebocontrolledrandomizedstudytoevaluatetheweightgaindrugmirtazapinetransdermalointmentincatswithunintendedweightloss AT quimbyjessicam doubleblindplacebocontrolledrandomizedstudytoevaluatetheweightgaindrugmirtazapinetransdermalointmentincatswithunintendedweightloss AT hutianhua doubleblindplacebocontrolledrandomizedstudytoevaluatetheweightgaindrugmirtazapinetransdermalointmentincatswithunintendedweightloss AT labelledaizie doubleblindplacebocontrolledrandomizedstudytoevaluatetheweightgaindrugmirtazapinetransdermalointmentincatswithunintendedweightloss AT buhleswilliam doubleblindplacebocontrolledrandomizedstudytoevaluatetheweightgaindrugmirtazapinetransdermalointmentincatswithunintendedweightloss |